Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share
-
Shares outstanding
-
41,123,390
-
Total 13F shares
-
20,235,741
-
Share change
-
-1,430,007
-
Total reported value
-
$19,376,340
-
Price per share
-
$0.96
-
Number of holders
-
16
-
Value change
-
-$1,268,448
-
Number of buys
-
6
-
Number of sells
-
9
Institutional Holders of Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share (ACHL) as of Q1 2023
As of 31 Mar 2023,
Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share (ACHL) was held by
16 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,235,741 shares.
The largest 10 holders included
Syncona Portfolio Ltd, BAKER BROS. ADVISORS LP, Artal Group S.A., Redmile Group, LLC, Point72 Asset Management, L.P., RENAISSANCE TECHNOLOGIES LLC, MORGAN STANLEY, AXA S.A., MILLENNIUM MANAGEMENT LLC, and Forefront Analytics, LLC.
This page lists
16
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.